(Q46081666)

19 December 2017

title

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy (English)

1 reference

19 December 2017

1 reference

1 reference

John T Leppert

5

0 references

author name string

Allan J Pantuck

1

1 reference

19 December 2017

David B Seligson

2

1 reference

19 December 2017

Tobias Klatte

3

1 reference

19 December 2017

Hong Yu

4

1 reference

19 December 2017

Laurence Moore

6

1 reference

19 December 2017

Timothy O'Toole

7

1 reference

19 December 2017

Jay Gibbons

8

1 reference

19 December 2017

Arie S Belldegrun

9

1 reference

19 December 2017

Robert A Figlin

10

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

19 December 2017

published in

Cancer

1 reference

19 December 2017

volume

109

1 reference

19 December 2017

page(s)

2257-2267

1 reference

19 December 2017

issue

11

1 reference

19 December 2017

Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Growing roles for the mTOR pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Upstream and downstream of mTOR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Akt signaling and cancer: surviving but not moving on.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Studies on the mechanism of resistance to rapamycin in human cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22677

7 January 2021

Identifiers

DOI

10.1002/CNCR.22677

1 reference

19 December 2017

PubMed ID

17440983

1 reference

19 December 2017